Souhaitez-vous accéder aux communiqués récents ?

Presentations highlight therapy-induced senescence as a new opportunity and reinforce STX-1’s potential as a differentiated approach in solid tumors.

At AACR 2026, Callio Therapeutics will present data that highlight the potential of CLIO-8221 as a therapeutic option for HER2-expressing cancers

BioNTech gab heute positive Ergebnisse aus der primären Analyse einer Phase-2-Kohorte mit Trastuzumab Pamirtecan bei HER2+ Gebärmutterkrebs bekannt.

BioNTech today announced positive results from the primary analysis of a Phase 2 cohort evaluating trastuzumab pamirtecan in HER2+ endometrial cancer.

Collaboration leverages OBT's proprietary OGAP®-Verify discovery platform and drug development capabilities in alignment with BMS’s expertise to advance selected novel oncology targets This is OBT’s...

Dosing of the first patient in the Phase 1 clinical trial of ADCX-020.

Präsentationen zeigen Fortschritte in BioNTechs spätklinischen Programmen im Bereich Lungenkrebs und unterstreichen das Potenzial des differenzierten Unternehmensportfolios, welches Immunmodulatoren,...

Presentations showcase progress in BioNTech’s late-stage lung cancer programs, reinforcing the potential of the Company’s differentiated portfolio spanning immunomodulators, antibody-drug conjugates,...

Data presented at 16th World ADC London Summit with lead programme in colorectal cancer highlight the promise of Promatix’s proteomics-based platform to optimise cis-bispecific antibody-drug conjugate...

The collaboration will inform patient selection for treatment with STX-1, a first-in-class senolytic ADC directed against DPP4/CD26.